CA3078570A1 - Formulations for enteric delivery of therapeutic agents - Google Patents

Formulations for enteric delivery of therapeutic agents Download PDF

Info

Publication number
CA3078570A1
CA3078570A1 CA3078570A CA3078570A CA3078570A1 CA 3078570 A1 CA3078570 A1 CA 3078570A1 CA 3078570 A CA3078570 A CA 3078570A CA 3078570 A CA3078570 A CA 3078570A CA 3078570 A1 CA3078570 A1 CA 3078570A1
Authority
CA
Canada
Prior art keywords
formulation
therapeutic agent
nanoparticles
insulin
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3078570A
Other languages
English (en)
French (fr)
Inventor
Indu Javeri.
Kaliappanadar Nellaiappan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Curirx Inc
Original Assignee
Curirx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curirx Inc filed Critical Curirx Inc
Publication of CA3078570A1 publication Critical patent/CA3078570A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
CA3078570A 2016-10-12 2017-10-12 Formulations for enteric delivery of therapeutic agents Pending CA3078570A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15/291,480 2016-10-12
US15/291,480 US11491114B2 (en) 2016-10-12 2016-10-12 Formulations for enteric delivery of therapeutic agents
PCT/US2017/056320 WO2018071655A1 (en) 2016-10-12 2017-10-12 Formulations for enteric delivery of therapeutic agents

Publications (1)

Publication Number Publication Date
CA3078570A1 true CA3078570A1 (en) 2018-04-19

Family

ID=61830540

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3078570A Pending CA3078570A1 (en) 2016-10-12 2017-10-12 Formulations for enteric delivery of therapeutic agents

Country Status (8)

Country Link
US (2) US11491114B2 (https=)
EP (1) EP3525772A4 (https=)
JP (1) JP7046081B2 (https=)
KR (2) KR102580705B1 (https=)
CN (1) CN110049759A (https=)
AU (2) AU2017341753B2 (https=)
CA (1) CA3078570A1 (https=)
WO (1) WO2018071655A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019097251A1 (en) * 2017-11-17 2019-05-23 Intract Pharma Limited Novel compositions
BR112021019612A2 (pt) * 2019-04-01 2021-11-30 Genentech Inc Formulações, recipiente, artigo de fabricação, método para produzir a formulação e método para inibir a agregação de uma proteína presente em uma solução aquosa
CN111743880B (zh) * 2020-06-05 2022-03-08 浙江大学医学院附属第一医院 一种单抗类药物口服纳米-微球制剂及其制备方法
US11365248B2 (en) 2020-06-29 2022-06-21 Anovent Pharmaceutical (U.S.), Llc Formulation of tocilizumab and method for treating COVID-19 by inhalation

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL68769A (en) 1983-05-23 1986-02-28 Hadassah Med Org Pharmaceutical compositions containing insulin for oral administration
JPS6051106A (ja) * 1983-08-31 1985-03-22 Yamanouchi Pharmaceut Co Ltd 塩酸アモスラロ−ル持続性製剤
WO1993000077A1 (en) 1991-06-21 1993-01-07 University Of Cincinnati Orally administrable therapeutic proteins and method of making
ATE167396T1 (de) 1993-02-22 1998-07-15 Alza Corp Mittel zur oralen gabe von wirkstoffen
AU698393B2 (en) 1994-06-24 1998-10-29 Immunex Corporation Controlled release polypeptide compositions and methods of treating inflammatory bowel disease
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US5916595A (en) * 1997-12-12 1999-06-29 Andrx Pharmaceutials, Inc. HMG co-reductase inhibitor
FR2775435B1 (fr) 1998-02-27 2000-05-26 Bioalliance Pharma Nanoparticules comprenant au moins un polymere et au moins un compose apte a complexer un ou plusieurs principes actifs
FR2786098B1 (fr) * 1998-11-20 2003-05-30 Flamel Tech Sa Particules a base de polyaminoacide(s) et susceptibles d'etre utilisees comme vecteurs de principe(s) actif(s), suspension colloidale les comprenant et leurs procedes de fabrication
EP1429731B1 (en) 2001-09-19 2007-01-03 Elan Pharma International Limited Nanoparticulate insulin formulations
US20040234602A1 (en) 2001-09-21 2004-11-25 Gina Fischer Polymer release system
US20040038303A1 (en) * 2002-04-08 2004-02-26 Unger Gretchen M. Biologic modulations with nanoparticles
AU2004277419B2 (en) * 2003-09-30 2007-10-11 Brown University Research Foundation Nanoparticulate therapeutic biologically active agents
US20050170004A1 (en) 2003-10-31 2005-08-04 Vered Rosenberger Nanoparticles for drug delivery
KR100638041B1 (ko) * 2003-12-24 2006-10-23 주식회사 삼양사 수용성 약물의 경구투여용 나노입자 조성물 및 그의제조방법
US20040224019A1 (en) 2004-03-03 2004-11-11 Adi Shefer Oral controlled release system for targeted drug delivery into the cell and its nucleus for gene therapy, DNA vaccination, and administration of gene based drugs
US7282194B2 (en) 2004-10-05 2007-10-16 Gp Medical, Inc. Nanoparticles for protein drug delivery
US7541028B2 (en) 2005-01-04 2009-06-02 Gp Medical, Inc. Nanoparticles for monoclonal antibody delivery
US7291598B2 (en) 2005-01-04 2007-11-06 Gp Medical, Inc. Nanoparticles for protein drug delivery
EP1933862B1 (en) 2005-09-06 2014-03-26 Oramed Pharmaceuticals Inc. Methods and compositions for oral administration of proteins
WO2007032018A1 (en) * 2005-09-15 2007-03-22 Council Of Scientific And Industrial Research pH SENSITIVE NANOPARTICLE FORMULATION FOR ORAL DELIVERY OF PROTEINS/PEPTIDES
US20080241260A1 (en) * 2005-09-28 2008-10-02 Padma Venkitachalam Devarajan Compositions for Enhanced Absorption of Biologically Active Agents
WO2008031770A2 (en) 2006-09-12 2008-03-20 Cosmo Technologies Ltd Pharmaceutical compositions for the oral or rectal administration of protein substances
WO2008073558A2 (en) 2006-10-05 2008-06-19 The Johns Hopkins University Water-dispersible oral, parenteral, and topical formulations for poorly water soluble drugs using smart polymeric nanoparticles
WO2008065502A1 (en) * 2006-11-29 2008-06-05 Pfizer Products Inc. Pharmaceutical compositions based on a) nanoparticles comprising enteric polymers and b) casein
US20100215747A1 (en) * 2007-07-13 2010-08-26 Corey Jay Bloom Nanoparticles comprising ionizable, poorly water soluble cellulosic polymers
US9233078B2 (en) * 2007-12-06 2016-01-12 Bend Research, Inc. Nanoparticles comprising a non-ionizable polymer and an Amine-functionalized methacrylate copolymer
CN102083423A (zh) * 2008-05-06 2011-06-01 葛兰素集团有限公司 生物活性剂的囊封方法
JP5841708B2 (ja) * 2008-07-01 2016-01-13 日東電工株式会社 表面被覆微粒子の医薬組成物
US20100021549A1 (en) 2008-07-28 2010-01-28 Flamel Technologies, S.A. Microparticle oral form useful for the modified release of nanoparticles
FR2934161B1 (fr) * 2008-07-28 2010-09-17 Flamel Tech Sa Forme orale microparticulaire utile pour la liberation modifiee de nanoparticules.
GB0815852D0 (en) * 2008-09-01 2008-10-08 Unilever Plc Improvements relating to pharmaceutical compositions
WO2010113177A2 (en) 2009-03-31 2010-10-07 Reliance Life Sciences Pvt. Ltd. Oral insulin delivery systems for controlling diabetes
US8673359B2 (en) 2010-07-08 2014-03-18 Brown University Nanoparticle compositions and methods for improved oral delivery of active agents
CN102614498B (zh) * 2011-01-28 2014-12-17 四川科伦药物研究有限公司 一种胰岛素纳米粒及其制备方法
US20140120162A1 (en) 2011-06-06 2014-05-01 Perosphere Inc. Bioadhesive Drug Delivery Compositions
EP2548571A1 (en) * 2011-07-22 2013-01-23 Institut Curie Compositions having means for targeting at least one antigen to dendritic cells
US8859004B2 (en) 2011-08-04 2014-10-14 Nano And Advanced Materials Institute Limited pH-sensitive nanoparticles for oral insulin delivery
CN102908332B (zh) * 2011-08-04 2014-04-16 纳米及先进材料研发院有限公司 用于口服胰岛素递送的包含阳离子纳米粒子的肠溶包衣胶囊
US9101547B2 (en) 2011-08-04 2015-08-11 Nano And Advanced Materials Institute Limited Enteric-coated capsule containing cationic nanoparticles for oral insulin delivery
CN104094119A (zh) 2011-10-21 2014-10-08 斯特姆詹尼克斯公司 用于胞内传递生物活性分子的官能化纳米粒子
EP2802314B1 (en) * 2012-01-13 2020-11-25 XSpray Microparticles AB A method for producing stable, amorphous hybrid nanoparticles comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix- forming component.
EP3778696A1 (en) 2012-04-23 2021-02-17 NanoProteagen Ltd. Polymeric nanoparticles and a process of preparation thereof
CN105142631A (zh) * 2013-01-14 2015-12-09 健康诊所有限公司 抗癌药物和用途
US9833522B2 (en) * 2013-12-23 2017-12-05 The Research Foundation For The State University Of New York Graphene-based contrast agents for photoacoustic and thermoacoustic tomography and method of use
WO2015181344A1 (en) * 2014-05-30 2015-12-03 AbbVie Deutschland GmbH & Co. KG Nanoencapsulation of antigen-binding molecules
US9370488B2 (en) 2014-07-21 2016-06-21 Kimia Zist Parsian Method and system for synthesizing nanocarrier based long acting drug delivery system for insulin
PT107846B (pt) * 2014-08-01 2019-03-22 Hovione Farm S A Produção de nano- partículas de dispersões sólidas amorfas por co-precipitação controlada
US9937256B2 (en) 2015-01-14 2018-04-10 Board Of Regents, The University Of Texas System Hydrogels for delivery of therapeutic compounds
CN104739806B (zh) * 2015-04-17 2018-04-03 黑龙江大学 口服胰岛素复合微囊及制备方法
CN105056212B (zh) * 2015-07-14 2018-06-15 江西省药物研究所 一种提高胰岛素口服结肠吸收的壳聚糖纳米粒及制备方法

Also Published As

Publication number Publication date
AU2017341753A1 (en) 2019-05-30
CN110049759A (zh) 2019-07-23
US12594246B2 (en) 2026-04-07
BR112019007539A2 (pt) 2019-07-02
US20180098946A1 (en) 2018-04-12
AU2017341753B2 (en) 2023-12-07
US20230034964A1 (en) 2023-02-02
JP2019534897A (ja) 2019-12-05
EP3525772A1 (en) 2019-08-21
KR102580705B1 (ko) 2023-09-19
US11491114B2 (en) 2022-11-08
AU2024201438A1 (en) 2024-03-21
JP7046081B2 (ja) 2022-04-01
EP3525772A4 (en) 2020-06-03
WO2018071655A1 (en) 2018-04-19
KR20190086446A (ko) 2019-07-22
KR20230135694A (ko) 2023-09-25

Similar Documents

Publication Publication Date Title
US12594246B2 (en) Formulations for enteric delivery of therapeutic agents
ES2700278T3 (es) Formulaciones para efectores de la unión estrecha
JP2023109799A (ja) 治療用又は診断用薬剤を含む粒子並びにその懸濁液及び使用方法
US11471422B2 (en) Stealth, targeted nanoparticles (STN) for oral drug delivery
CA2936493C (en) Nanoencapsulation of hydrophilic active compounds
US20100111984A1 (en) Nanospheres encapsulating bioactive material and method for formulation of nanospheres
AU2018287142B2 (en) Albumin nanoparticles for the treatment of cancer and ocular diseases
CN105412935A (zh) 一种基于n-(2-羟丙基)甲基丙烯酰胺聚合物的纳米粒及其制备方法
JP2013525351A (ja) ナノ粒子の医薬組成物
WO2002064112A2 (en) Therapeutic agents complexed with calcium phosphate and encased by casein
MX2007007942A (es) Composiciones de material nanoparticulado y de liberacion controlada que comprenden una cefalosporina.
MX2008011069A (es) Formulaciones de carvedilol en nanoparticulas.
KR101319773B1 (ko) 핵산-함유 점막점착성 활성 성분을 포함한 다입자 투여 형태, 및 이러한 투여 형태의 제조 방법
JP2025020319A (ja) テルリプレシン組成物およびその使用方法
CN101287453A (zh) 包含头孢菌素的毫微粒和控制释放组合物
CN106924184B (zh) 一种眼部玻璃体注射用多囊脂质体及其制备方法
BR112019007539B1 (pt) Formulação oral de um agente terapêutico, método de preparação de uma formulação administrável por via oral de um agente terapêutico e uso da referida formulação oral
Mohammed Development of Once-Daily Mycophenolate Mofetil Sustained Release Oral Nanoparticles
JP2010514679A (ja) 制御放出組成物及び方法

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220908

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20240816

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20241216

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250207

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250407

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250528

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250609

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250609

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251003

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251003

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251127